Charles Schwab Investment Management Inc. Acquires 41,458 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Charles Schwab Investment Management Inc. increased its holdings in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 6.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 695,947 shares of the company’s stock after purchasing an additional 41,458 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.82% of Syndax Pharmaceuticals worth $13,397,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the business. Intech Investment Management LLC bought a new position in Syndax Pharmaceuticals in the third quarter valued at approximately $429,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in shares of Syndax Pharmaceuticals during the third quarter worth $15,165,000. First Turn Management LLC lifted its position in Syndax Pharmaceuticals by 85.4% in the 3rd quarter. First Turn Management LLC now owns 1,187,165 shares of the company’s stock valued at $22,853,000 after acquiring an additional 546,776 shares in the last quarter. Quest Partners LLC boosted its stake in Syndax Pharmaceuticals by 31.0% in the 3rd quarter. Quest Partners LLC now owns 17,858 shares of the company’s stock worth $344,000 after purchasing an additional 4,223 shares during the period. Finally, Simplify Asset Management Inc. increased its holdings in Syndax Pharmaceuticals by 62.5% during the 3rd quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company’s stock worth $2,352,000 after purchasing an additional 46,992 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on SNDX shares. HC Wainwright upped their price objective on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the stock a “buy” rating in a research report on Monday, November 18th. Citigroup upped their price target on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, November 19th. StockNews.com downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. JPMorgan Chase & Co. increased their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group raised their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, Syndax Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $37.64.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX stock opened at $17.01 on Monday. Syndax Pharmaceuticals, Inc. has a 52-week low of $15.00 and a 52-week high of $25.34. The stock has a market cap of $1.45 billion, a price-to-earnings ratio of -4.69 and a beta of 0.86. The firm’s 50-day moving average is $18.29 and its 200-day moving average is $19.65.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The business had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same period in the previous year, the business earned ($0.73) earnings per share. Sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current fiscal year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).